Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.
Parabilis Medicines (PBLS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
● GlobeNewsWireNov 12, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in desmoid tumors Reached alig…
● GlobeNewsWireNov 3, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Parabilis Medicines to Participate in Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unloc…
Parabilis Medicines: Bullish On Zolucatetide's Broad Oncology Potential
Zolucatetide gives PBLS potential in desmoid tumors, but it also has other Wnt-driven indications that could grow its TAM over time. PBLS's PEDESTAL trial is now a clearer R&D path, as long as early responses are corrobo…
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
Parabilis Medicines NASDAQ: PBLS presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology Congress in Madrid, re…
● GlobeNewsWireOct 24, 2026 · 08:45 ETCOMPANY'S OWN WORDS
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unloc…
Parabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For Free
Parabilis Medicines, Inc. is rated a speculative Buy due to its innovative peptide platform and strong rare-disease oncology pipeline. Lead asset zolucatetide (zolu) shows robust early efficacy in desmoid tumors and cran…
● GlobeNewsWireOct 19, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumors Company to host we…
● GlobeNewsWireOct 14, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors…
Parabilis Medicines (NASDAQ:PBLS) Shares Gap Up – Here’s What Happened
Parabilis Medicines, Inc. (NASDAQ: PBLS - Get Free Report)'s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $31.20, but opened at $32.84. Parabilis Medicines shares last traded at $…
● GlobeNewsWireSep 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlo…
● GlobeNewsWireAug 25, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unloc…
Article counts from the last market-wide feed page, across every symbol we track and not just PBLS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.